Literature DB >> 9188631

Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity.

M N Ruesch1, L A Laimins.   

Abstract

The E6 and E7 proteins from the high-risk human papillomaviruses (HPVs) bind and inactivate the tumor suppressor proteins p53 and Rb, respectively. In HPV-positive cells, expression of E6 proteins from high-risk types results in increased turnover of p53, which leads to an abrogation of p21-mediated G1/S arrest in response to DNA-damaging agents. In contrast, keratinocytes which express E7 alone have increased levels of p53 but, interestingly, also fail to undergo a G1/S arrest. We investigated the mechanism by which E7 bypasses this p21 arrest by using both keratinocytes which stably express E7 as well as U20S cells which stably or transiently express E7. We observed that E7 does not affect the induction of p21 synthesis by p53. While glutathione S-transferase (GST)-E7 bound a low level of in vitro-translated p21, we were unable to detect E7 and p21 in the same complex by GST-E7 binding assays or immunoprecipitations from cell extracts. Furthermore, E7 did not prevent p21-mediated inhibition of cyclin E kinase activity. In keratinocytes expressing E7, increased levels of p53, p21, and cyclin E, as well as increased cyclin E kinase activity, were observed. To determine if this increase in cyclin E activity was necessary for E7's ability to overcome p21-mediated G1/S arrest, we examined U20S cells in which cyclin E levels are not increased in response to E7 expression. U20S cells which stably express E7 were found to initiate DNA synthesis in the presence of DNA-damaging agents despite the inhibition of cyclin E activity by p21. In transient assays, cotransfection of E7 or E2F-1 along with p21 into U20S cells rescued G1 arrest and resulted in S-phase entry, as measured by the ability to incorporate bromodeoxyuridine. These data indicate that E7 is able to overcome G1/S arrest without directly affecting p21 function and likely acts through deregulation of E2F activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9188631      PMCID: PMC191799          DOI: 10.1128/JVI.71.7.5570-5578.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences.

Authors:  K Münger; C L Yee; W C Phelps; J A Pietenpol; H L Moses; P M Howley
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

2.  The E2F transcription factor is a cellular target for the RB protein.

Authors:  S P Chellappan; S Hiebert; M Mudryj; J M Horowitz; J R Nevins
Journal:  Cell       Date:  1991-06-14       Impact factor: 41.582

3.  Mutational analysis of human papillomavirus type 16 E7 functions.

Authors:  S Watanabe; T Kanda; H Sato; A Furuno; K Yoshiike
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

4.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.

Authors:  M Scheffner; B A Werness; J M Huibregtse; A J Levine; P M Howley
Journal:  Cell       Date:  1990-12-21       Impact factor: 41.582

5.  The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.

Authors:  N Dyson; P M Howley; K Münger; E Harlow
Journal:  Science       Date:  1989-02-17       Impact factor: 47.728

6.  Association of human papillomavirus types 16 and 18 E6 proteins with p53.

Authors:  B A Werness; A J Levine; P M Howley
Journal:  Science       Date:  1990-04-06       Impact factor: 47.728

7.  The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells.

Authors:  C L Halbert; G W Demers; D A Galloway
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

8.  Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage.

Authors:  T D Kessis; R J Slebos; W G Nelson; M B Kastan; B S Plunkett; S M Han; A T Lorincz; L Hedrick; K R Cho
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

Review 9.  Genital human papillomavirus infection.

Authors:  D R Lowy; R Kirnbauer; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

10.  Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family.

Authors:  A Koff; F Cross; A Fisher; J Schumacher; K Leguellec; M Philippe; J M Roberts
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

View more
  31 in total

Review 1.  Strategies in subversion: de-regulation of the mammalian cell cycle by viral gene products.

Authors:  C Swanton; N Jones
Journal:  Int J Exp Pathol       Date:  2001-02       Impact factor: 1.925

2.  Intranuclear localization of human papillomavirus 16 E7 during transformation and preferential binding of E7 to the Rb family member p130.

Authors:  K Smith-McCune; D Kalman; C Robbins; S Shivakumar; L Yuschenkoff; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 3.  Molecular interactions of 'high risk' human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression.

Authors:  Oishee Chakrabarti; Sudhir Krishna
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

4.  Degradation of p53, not telomerase activation, by E6 is required for bypass of crisis and immortalization by human papillomavirus type 16 E6/E7.

Authors:  H R McMurray; D J McCance
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 5.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

6.  HPV-16 E7 reveals a link between DNA replication stress, fanconi anemia D2 protein, and alternative lengthening of telomere-associated promyelocytic leukemia bodies.

Authors:  Nicole Spardy; Anette Duensing; Elizabeth E Hoskins; Susanne I Wells; Stefan Duensing
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

7.  Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest.

Authors:  Don X Nguyen; Thomas F Westbrook; Dennis J McCance
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

8.  Anchorage-independent transcription of the cyclin A gene induced by the E7 oncoprotein of human papillomavirus type 16.

Authors:  A Schulze; B Mannhardt; K Zerfass-Thome; W Zwerschke; P Jansen-Dürr
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

9.  Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells.

Authors:  Anna-Marija Helt; Jens Oliver Funk; Denise A Galloway
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  E7 abolishes raf-induced arrest via mislocalization of p21(Cip1).

Authors:  Thomas F Westbrook; Don X Nguyen; Barry R Thrash; Dennis J McCance
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.